Resistance of SMMC-7721 hepatoma cells to etoposide in hypoxia is reversed by VEGF inhibitor

Shi,Shanshan; Yuan,Chenxing; Zhuang,Kaizan; Liang,Guikai; Yao,Zhangting; Wang,Duoduo; Weng,Qinjie; Cao,Ji; Luo,Peihua; Zhu,Hong; Ding,Ling; Ma,Shenglin

doi:10.3892/mmr.2015.3217

Resistance of SMMC-7721 hepatoma cells to etoposide in hypoxia is reversed by VEGF inhibitor

Authors:
- Shanshan Shi
- Chenxing Yuan
- Kaizan Zhuang
- Guikai Liang
- Zhangting Yao
- Duoduo Wang
- Qinjie Weng
- Ji Cao
- Peihua Luo
- Hong Zhu
- Ling Ding
- Shenglin Ma
View Affiliations

Affiliations: Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China, Department of Pharmacy, Fenghua Hospital, Ningbo, Zhejiang 315040, P.R. China, Department of Pharmacy, Hangzhou First People's Hospital, Hangzhou, Zhejiang 310009, P.R. China
Published online on: January 16, 2015 https://doi.org/10.3892/mmr.2015.3217
Pages: 3842-3847

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypoxia is associated with resistance to chemotherapy in a number of human cancer types; particularly in hepatocellular carcinoma (HCC), which is a highly vascularized tumor. To develop a potential combination therapy strategy that is capable of overcoming the hypoxia‑induced insensitivity to chemotherapy, the HCC cell SMMC‑7721 was employed to investigate the hypoxia‑induced chemoresistance to etoposide. Increased levels of hypoxia‑inducible factor‑1α (HIF‑1α) and vascular endothelial growth factor (VEGF) were observed when SMMC‑7721 cells were exposed to hypoxia, and exposure of tumor cells to hypoxia impaired etoposide‑induced DNA damage, as indicated by the failure of upregulation of γHA2X. Etoposide‑induced apoptosis and cell cycle arrest of SMMC‑7721 was also impaired in hypoxia. However, co‑treatment with anti‑VEGF significantly restored etoposide‑induced cell apoptosis and cell cycle arrest, as indicated by the elimination of B‑cell lymphoma 2 (Bcl‑2), procaspase 3, cyclin B1 and Cdc2. Furthermore, anti‑VEGF eliminated phosphorylation of AKT, ERK and IκB‑α resulting from hypoxia, suggesting the involvement of VEGF in the activation of the survival pathways. In conclusion, the present study suggests a significant role of VEGF in the chemoresistance of etoposide in hypoxia. A rational chemotherapy should be developed based on a combination of etoposide and anti‑VEGF.

View Figures

View References

1	Höckel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
2	Carroll VA and Ashcroft M: Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res. 66:6264–6270. 2006. View Article : Google Scholar : PubMed/NCBI
3	Semenza GL, Shimoda LA and Prabhakar NR: Regulation of gene expression by HIF-1. Novartis Found Symp. 272:33–36. 2006.
4	Schnitzer SE, Weigert A, Zhou J, et al: Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Mol Cancer Res. 7:393–401. 2009. View Article : Google Scholar : PubMed/NCBI
5	Yang B, Fan L, Fang L, et al: Hypoxia-mediated fenretinide (4-HPR) resistance in childhood acute lymphoblastic leukemia cells. Cancer Chemother Pharmacol. 58:540–546. 2006. View Article : Google Scholar : PubMed/NCBI
6	Flamant L, Notte A, Ninane N, et al: Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol Cancer. 9:1912010. View Article : Google Scholar : PubMed/NCBI
7	Sermeus A, Cosse JP, Crespin M, et al: Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity. Mol Cancer. 7:27–31. 2008. View Article : Google Scholar : PubMed/NCBI
8	Wang D, Weng Q, Zhang L, et al: VEGF and Bcl-2 interact via MAPKs signaling pathway in the response to hypoxia in neuroblastoma. Cell Mol Neurobiol. 29:391–401. 2009. View Article : Google Scholar
9	Das B, Yeger H, Tsuchida R, et al: A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res. 65:7267–7275. 2005. View Article : Google Scholar : PubMed/NCBI
10	Tsuchida R, Das B, Yeger H, et al: Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. Oncogene. 27:3923–3934. 2008. View Article : Google Scholar : PubMed/NCBI
11	Lee TH, Seng S, Sekine M, et al: Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 4:186–191. 2007. View Article : Google Scholar
12	Erler JT, Cawthorne CJ, Williams KJ, et al: Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol. 24:2875–2889. 2004. View Article : Google Scholar : PubMed/NCBI
13	Jeng KS, Sheen IS, Wang YC, et al: Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J Gastroenterol. 10:643–648. 2004.PubMed/NCBI
14	Jinno K, Tanimizu M, Hyodo I, et al: Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol. 33:376–382. 1998. View Article : Google Scholar : PubMed/NCBI
15	Kwak BK, Shim HJ, Park ES, et al: Hepatocellular carcinoma: correlation between vascular endothelial growth factor level and degree of enhancement by multiphase contrast-enhanced computed tomography. Invest Radiol. 36:487–492. 2001. View Article : Google Scholar : PubMed/NCBI
16	Pang R and Poon RT: Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 242:151–167. 2006. View Article : Google Scholar : PubMed/NCBI
17	Sun W, Sohal D, Haller DG, et al: Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer. 117:3187–3192. 2011. View Article : Google Scholar : PubMed/NCBI
18	Thomas MB, Morris JS, Chadha R, et al: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 27:843–850. 2009. View Article : Google Scholar : PubMed/NCBI
19	Kaseb AO, Garrett-Mayer E, Morris JS, et al: Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology. 82:67–74. 2012. View Article : Google Scholar : PubMed/NCBI
20	Smart DJ, Halicka HD, Schmuck G, et al: Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone. Mutat Res. 641:43–47. 2008. View Article : Google Scholar : PubMed/NCBI
21	Brady CA, Jiang D, Mello SS, et al: Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 145:571–583. 2011. View Article : Google Scholar : PubMed/NCBI
22	Richard S, Geneviève CP, Lisa JF, et al: hypoxia-inducible factor-1 activity associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther. 7:1961–1973. 2008. View Article : Google Scholar
23	Pommier Y, Sordet O, Antony S, et al: Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 23:2934–2949. 2004. View Article : Google Scholar : PubMed/NCBI
24	Jung Y, Isaacs JS, Lee S, et al: Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem J. 370:1011–1017. 2003. View Article : Google Scholar
25	Rius J, Guma M, Schachtrup C, et al: NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 453:807–811. 2008. View Article : Google Scholar : PubMed/NCBI
26	Perkins ND: Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene. 25:6717–6730. 2006. View Article : Google Scholar : PubMed/NCBI
27	Perkins ND and Gilmore TD: Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 13:759–772. 2006. View Article : Google Scholar : PubMed/NCBI
28	Cummins EP, Berra E, Comerford KM, et al: Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA. 103:18154–18159. 2006. View Article : Google Scholar : PubMed/NCBI
29	Unruh A, Ressel A, Mohamed HG, et al: The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene. 22:3213–3220. 2003. View Article : Google Scholar : PubMed/NCBI
30	Le QT, Denko NC and Giaccia AJ: Hypoxic gene expression and metastasis. Cancer Metastasis Rev. 23:293–310. 2004. View Article : Google Scholar : PubMed/NCBI
31	Sullivan R and Graham CH: Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol Cancer Ther. 8:1702–1713. 2009. View Article : Google Scholar : PubMed/NCBI
32	Rohwer N, Dame C, Haugstetter A, et al: Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One. 5:120382010. View Article : Google Scholar
33	Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocrine Rev. 25:581–611. 2004. View Article : Google Scholar
34	Pal S, Datta K and Mukhopadhyay D: Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 61:6952–6957. 2001.PubMed/NCBI
35	Ravi R, Mookerjee B, Bhujwalla ZM, et al: Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14:34–44. 2000.PubMed/NCBI
36	Yang J, Ahmed A, Poon E, et al: Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol. 29:2243–2253. 2009. View Article : Google Scholar : PubMed/NCBI
37	Walmsley SR, Print C, Farahi N, et al: Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 201:105–115. 2005. View Article : Google Scholar : PubMed/NCBI
38	Wang CY, Cusack JC, Liu R, et al: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med. 5:412–417. 1999. View Article : Google Scholar : PubMed/NCBI